Seroprevalence of COVID-19 (cov prevalence)

Sohag University

Status: Completed

Conditions: Covid19

Treatments: Diagnostic Test: laboratory test

Study type: Observational

Funder types: Other

Identifiers

NCT04941053

Soh-Med-21-04-33

Details and patient eligibility

About

Coronavirus disease pandemic has been started in late 2019. Since this date, the number of cases has been increased reaching 32.7 million cases worldwide in 27 September, 2020. . Herd immunity is achieved when enough people become immune to a virus to stop its spread. Around 70% to 90% of a population needs to be immune to protect the uninfected. In A Spanish study of more than 30,000 people estimates that around just 5% of the Spanish population has developed antibodies

Full description

Aims of work:

A cross-sectional study to detect the seroprevalence to COVID 19 in chronic hemodialysis patients and compare it with the COVID 19 seroprevalence in healthy control in Sohag governorate Egypt

Methods:

After taken informed consent according to Sohag University Ethical Committee A questionnaire on coronavirus symptoms will be asked including epidemiological characters and history of previous COVID 19 infection and infection control measures to prevent it

5 ml of the blood sample will be taken for IgG antibodies testing with a chemiluminescent microparticle immunoassay.

Enrollment: 300 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patient accept to participate

Exclusion criteria

• vaccinated people

Trial design

300 participants in 2 patient groups

group 1 chronic haemodialysis patients

Description:

seroprevalnce of COVID 19

Treatment:

Diagnostic Test: laboratory test

healthy control

Description:

seroprevalnce of COVID 19

Treatment:

Diagnostic Test: laboratory test